Latest news with #MindScapeRetreat
Associated Press
03-05-2025
- Health
- Associated Press
MindScape Retreat Releases Landmark Case Study Showing 70% Average Symptom Improvement in Parkinson's Patients Following Ibogaine Treatment in Mexico
Miami, FL May 02, 2025 --( )-- MindScape Retreat, a pioneer in clinical psychedelic therapy programs, has released the results of a transformative case series evaluating the safety and efficacy of a 14-day ibogaine treatment program for Parkinson's disease. The findings suggest that ibogaine, a naturally occurring psychoactive alkaloid, may offer disease-modifying benefits in PD through its unique neuroregenerative properties. The study tracked 30 patients with idiopathic Parkinson's disease (PD), ranging in age from 45 to 72, who attended the retreat's specialized ibogaine protocol between January and April 2025. Most were at Hoehn & Yahr stage 2–3, with moderate motor symptoms despite optimized conventional therapy. Key Findings from the Case Study - 52% average symptom relief was recorded within the first 3–4 days, following several days of titrated ibogaine therapy. - By Day 14, the average symptom reduction had reached 70%, with improvements observed in gait, bradykinesia, tremor, and muscle rigidity. - 25% of participants who continued low-dose microdosing (5–10 mg Ibogaine TA, 2–3 times per week) post-retreat experienced further improvement or maintained peak function at the 2-month follow-up. - No serious adverse events occurred. Side effects were mild and included nausea (40%), temporary dizziness (20%), and transient insomnia (15%). Program Design and Protocol The 14-day program utilized Ibogaine HCl and Ibogaine TA, administered in twice-daily doses (75–150 mg in the morning; 50–75 mg in the afternoon), adjusted based on each patient's response. Patients received: - Personalized ibogaine dosing under 24/7 medical monitoring - Daily UPDRS assessments (Unified Parkinson's Disease Rating Scale) - Electrocardiogram (EKG) and vital sign monitoring - Supplementary therapies including guided physical therapy, meditation, nutritional support, and optional 5-MeO-DMT integration sessions Treatment emphasized neuroplastic repair over mere symptom masking. Ibogaine and its active metabolite noribogaine are believed to upregulate Glial Cell Line-Derived Neurotrophic Factor (GDNF) – a protein shown in research to promote dopaminergic neuron survival and regrowth, potentially reversing PD pathology. Patient Outcomes: Restored Function and Mobility One standout case involved a 62-year-old male who arrived wheelchair-bound with severe bradykinesia and freezing of gait. By Day 4, he was walking with a cane. By Day 13, he was independently mobile for over 30 meters and able to board a plane home using only minor assistance. His motor score improved by 61%, and his family described the transformation as 'nothing short of miraculous.' Across the cohort: Gait and balance scores improved by 85% Bradykinesia improved by 70% Rigidity reduced by 65% Tremor severity dropped by 60% Most patients also reported enhanced mood, sleep quality, and cognitive clarity, reflecting the broad neurochemical modulation provided by noribogaine. Implications and Future Directions According to MindScape's medical team, these results suggest ibogaine may represent a new frontier in neurorestorative therapies for Parkinson's disease. Unlike standard dopamine-replacement drugs, ibogaine targets upstream mechanisms of disease progression, potentially slowing neurodegeneration. 'This is more than symptom control it's about restoring function. The evidence of sustained improvement and the role of neurotrophic support from ibogaine is compelling,' said Dr. Calderon, Medical Director at MindScape Retreat. MindScape plans to submit this case study for peer-reviewed publication and is currently coordinating a prospective observational follow-up study with academic partners to monitor long-term outcomes, including dopamine function and disease progression rates over 12+ months. About MindScape Retreat MindScape Retreat is a medically licensed psychedelic wellness center in Cozumel, Mexico, specializing in integrative ibogaine therapy for addiction, depression, trauma, and neurodegenerative conditions. The center offers evidence-based, physician-supervised programs combining plant medicine with clinical diagnostics, therapeutic integration, and long-term aftercare. MindScape Retreat Email: [email protected] Ibogaine Treatment for Parkinsons Case Study: Contact Information: MindScape Retreat Dr. Omar Calderon 786-761-7729 Contact via Email Read the full story here: MindScape Retreat Releases Landmark Case Study Showing 70% Average Symptom Improvement in Parkinson's Patients Following Ibogaine Treatment in Mexico Press Release Distributed by
Associated Press
25-04-2025
- Health
- Associated Press
MindScape Retreat in Cozumel, Mexico, Offers Innovative Ibogaine Therapy to Address Long-Term SSRI Effects and Serotonin Syndrome Risks
Miami, FL April 25, 2025 --( )-- MindScape Retreat, a licensed ibogaine treatment center located in Cozumel, Mexico, is pioneering a holistic approach to assist individuals in safely discontinuing Selective Serotonin Reuptake Inhibitors (SSRIs) and addressing associated long-term effects, including the risk of serotonin syndrome. Through medically supervised ibogaine therapy, an Ibogaine Retreat at MindScape Retreat aims to restore neurochemical balance and promote overall well-being. Understanding the Challenges of Long-Term SSRI Use While SSRIs are commonly prescribed for depression and anxiety, prolonged use has been associated with several adverse effects: Emotional Blunting: A diminished ability to experience emotions, affecting personal relationships and quality of life. Cognitive Impairments: Difficulties with memory, concentration, and decision-making. Sexual Dysfunction: Persistent issues such as decreased libido and anorgasmia, even after discontinuation. Withdrawal Symptoms: Challenges in tapering off SSRIs, including mood disturbances and physical discomfort. Moreover, SSRIs can increase the risk of serotonin syndrome, a potentially life-threatening condition resulting from excessive serotonin activity in the central nervous system. Symptoms can range from mild (tremors, sweating, confusion) to severe (high fever, seizures, loss of consciousness). The syndrome is more common than many realize, especially when SSRIs are combined with other serotonergic agents or supplements. Ibogaine: A Potential Path to Neurochemical Restoration Ibogaine, a naturally occurring alkaloid derived from the African iboga plant, offers a unique approach to addressing the neurochemical imbalances associated with long-term SSRI use. Unlike SSRIs, which increase serotonin levels by blocking its reuptake, ibogaine acts as a non-competitive inhibitor of the serotonin transporter (SERT), potentially helping to reset and rebalance neurotransmitter systems without causing excessive serotonin accumulation. Additionally, ibogaine has been shown to stimulate the release of neurotrophic factors such as Brain-Derived Neurotrophic Factor (BDNF) and Glial cell line-Derived Neurotrophic Factor (GDNF). These proteins support neuronal growth, differentiation, and survival, playing a crucial role in neuroplasticity—the brain's ability to reorganize and form new neural connections. By enhancing neuroplasticity, ibogaine may help reverse the structural and functional changes associated with long-term SSRI use. MindScape Retreat's Comprehensive Approach At MindScape Retreat, patients undergo thorough medical evaluations to ensure safety and suitability for ibogaine therapy. The retreat's programs integrate ibogaine treatment with supportive practices, including NAD+ infusions, to promote mitochondrial health and neurotransmitter balance. The serene setting of Cozumel provides an ideal environment for individuals seeking a transformative healing experience. About MindScape Retreat MindScape Retreat is dedicated to providing safe and effective ibogaine therapy for individuals seeking to overcome the challenges associated with long-term SSRI use. With a focus on holistic healing and neurochemical restoration, the retreat offers personalized care in a tranquil setting. For more information about MindScape Retreat and its ibogaine therapy programs, please visit Contact Information: MindScape Retreat Dr. Omar Calderon 786-761-7729 Contact via Email Read the full story here: MindScape Retreat in Cozumel, Mexico, Offers Innovative Ibogaine Therapy to Address Long-Term SSRI Effects and Serotonin Syndrome Risks Press Release Distributed by
